Clinical Trials
19 trialsNCT07527221 2026-06-01
Safety and Tolerability of ZE74-0282 in Healthy Volunteers
Eilean Therapeutics
Phase 1 Recruiting
NCT07441694 2026-05-29
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT07469891 2026-05-29
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
Phase 1 Recruiting
NCT07379125 2026-05-22
Therapeutic RSK1 Targeting in Myelofibrosis
Washington University School of Medicine
Phase 1 Recruiting
NCT04771572 2026-05-05
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Newave Pharmaceutical Inc
Phase 1 Recruiting
NCT06313593 2026-05-04
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT06034002 2026-04-17
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT06047886 2026-04-13
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
University of Alabama at Birmingham
Phase 1 Recruiting
NCT07008118 2026-04-06
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT07020533 2026-03-27
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Phase 1 Recruiting
NCT05936359 2026-03-24
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Incyte Corporation
Phase 1 Recruiting
NCT03326310 2025-12-29
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
University of Chicago
Phase 1 Recruiting
NCT06712810 2025-10-10
Q702 for the Treatment of Patients With Hematologic Malignancies
Mayo Clinic
Phase 1 Recruiting
NCT06378437 2025-08-19
A Study of GLB-001 in Patients With Myeloid Malignancies
Hangzhou GluBio Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05233618 2025-05-28
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
University of Virginia
Phase 1 Recruiting
NCT05423691 2025-04-13
TREG108
Cellenkos, Inc.
Phase 1 Recruiting
NCT05025488 2025-04-06
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
Icahn School of Medicine at Mount Sinai
Phase 1 Recruiting
NCT05488548 2025-01-14
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Epigenetix, Inc.
Phase 1 Recruiting
NCT06218628 2024-05-03
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Fox Chase Cancer Center
Phase 1 Recruiting